5,833,333 Shares Vitae Pharmaceuticals, Inc. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • March 24th, 2016 • Vitae Pharmaceuticals, Inc • Pharmaceutical preparations • New York
Vitae Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”) for whom Piper Jaffray & Co. (“PJC”) and BMO Capital Markets Corp. (“BMO” collectively with PJC, the “Representatives”) are acting as representatives, an aggregate of 5,833,333 shares (the “Firm Shares”) of the common stock, par value $0.0001 per share, of the Company (“Common Stock”). The Company also proposes to sell to the several Underwriters, at the option of the Underwriters, up to an additional 875,000 shares of Common Stock (the “Option Shares”). The Firm Shares and the Option Shares are hereinafter referred to collectively as the “Shares.”
